The EACR’s ‘Highlights in Cancer Research’ is a regular summary of the most interesting and impactful recent papers in cancer research, curated by the Board of the European Association for Cancer Research (EACR).
The list below appears in no particular order, and the summary information has been provided by the authors unless otherwise indicated.
Use the dropdown menu or ‘Previous’ and ‘Next’ buttons to navigate the list.
doi: 10.1038/s43018-025-01007-z.
Summary and graphical abstract by Alexandra Boitor, EACR Scientific Officer
Summary of the findings
Hormone receptor+HER2− (HR+HER2−) breast cancer is one of the most common subtypes of breast cancer. The first line of treatment for advanced stages of the disease (metastatic HR+HER2− breast cancer) is endocrine therapy in combination with three cyclin-dependent kinase 4/6 (CDK4/CDK6) inhibitors. Although cyclin-dependent kinase inhibitors have shown promising activity in some cases as adjuvants to endocrine therapy, many women with late-stage HR+HER2− breast cancer develop resistance and ultimately the disease progresses. A mounting body of research suggests that CDK4/CDK6 inhibitors may have an immunoenhancing function which may play a role in potentiating the mechanisms that may underlie the therapeutic efficacy. This raises the question if immune effects may be involved in the development of treatment resistance as well.
.
